Clinical Issues in Chronic Pain
Debates and Discussions About Therapeutically Targeting Nerve Growth Factor Signaling
Meeting Slides
Clinical Practice Guidelines
Chronic opioid therapy for chronic non-cancer pain: a review and comparison of treatment guidelines.
Cheung CW, et al. Pain Physician. 2014;17(5):401-414.
CDC guideline for prescribing opioids for chronic pain—United States, 2016.
Dowell D, et al. JAMA. 2016;315(15):1624-1645.
Patient Resources
American Chronic Pain Association
Information about conditions, management tools, advocacy, and support.
Centers for Disease Control and Prevention
Educational materials for patients about chronic pain and taking opioids.
International Association for the Study of Pain
List of local and national organizations dedicated to pain management, as well as a library of videos and articles for patient support.
U.S. Pain Foundation
Source for education, support, and advocacy for patients living with pain.
Clinical Assessment Tools
Pain BC
Collection of assessment tools to measure pain, pain-related anxiety, pain-related depression, and pain outcomes.
Pain Disability Index
Assess level of disruption in daily life caused by chronic pain.
Roland Morris Disability Questionnaire
Questionnaire to assess low back pain.
WOMAC Osteoarthritis Index
Scale to assess both knee and hip osteoarthritis pain.
Suggested Readings
Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis.
Birbara C, et al. J Pain Res. 2018;11:151-164.
Nerve growth factor and pain mechanisms.
Denk F, et al. Annu Rev Neurosci. 2017;40:307-325.
Relieving pain in America: a blueprint for transforming prevention, care, education, and research.
Institute of Medicine. Washington, DC: National Academies Press (US); 2011.
Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain.
Kivitz AJ, et al. Pain. 2013;154(7):1009-1021.
NGF—the TrkA to successful pain treatment.
Kumar V, Mahal BA. J Pain Res. 2012;5:279-287.
Emerging targets for the management of osteoarthritis pain.
Malfait AM, Miller RJ. Curr Osteoporos Rep. 2016;14(6):260-268.
Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.
Miller RE, et al. Clin Exp Rheumatol. 2017;35 (suppl 107[5]):85-87.
The discriminative validity of “nociceptive,” “peripheral neuropathic,” and “central sensitization” as mechanisms-based classifications of musculoskeletal pain.
Smart KM, et al. Clin J Pain. 2011;27(8):655-663.
Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee.
Tiseo PJ, et al. Pain. 2014;155(7):1245-1252.
What is this thing called pain?
Woolf CJ. J Clin Invest. 2010;120(11):3742-3744.
Interactive PresentationNGF Pathophysiology
Charles E. Argoff, MD
Debates and Discussions About Therapeutically Targeting Nerve Growth Factor Signaling
Module 1
Relevant Resources
Balancing the Benefits and Risk of Opioid-Based Therapy
Individualized Assessment and Mechanism-Based Multimodal Treatment
Responsible Opioid Prescribing to Achieve Individualized Functional Goals
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Proactive Diagnosis and Targeted Management
Selecting Patients and Optimizing Long-Term Outcomes
Proactive Diagnosis and Targeted Management
Consensus and Controversies for Responsible Opioid Prescribing
The Role of Nurses in Optimizing Long-term Outcomes
Evolving Best-Practice Strategies to Maximize Efficacy and Safety
A Focus on Patients With Opioid-Induced Constipation
Patient Selection, Treatment Initiation, and Ongoing Monitoring
Engaging With Patients About Opioid-Induced Constipation
The PCP’s Role in Timely Recognition and Referral
Expanding the Conversation on Opioid-Induced Constipation
